Milestone Pharmaceuticals (MIST) Prepaid Assets (2018 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Prepaid Assets came in at $1.0 million in Q2 2026, up 38.37% on a YoY basis from $748000.0 in Q2 2025, and down 14.46% quarter-over-quarter from $1.2 million in Q1 2026.
Analysis
Milestone Pharmaceuticals (MIST) Prepaid Assets (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has reported Prepaid Assets for 9 consecutive years, with $1.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Prepaid Assets rose 38.37% year-over-year to $1.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.0 million (up 38.37% YoY), and the FY2025 full-year result was $1.8 million, down 1.9% from the prior year.
- Prepaid Assets fell to $1.0 million in Q2 2026 per MIST's latest filing, from $1.2 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $7.0 million in Q3 2023 and bottomed at $748000.0 in Q2 2025.
- Historically, Prepaid Assets has averaged $3.2 million across 5 years, with a median of $2.6 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Prepaid Assets surged 55.84% in 2023, then tumbled 68.28% in 2024.
- Over 5 years, Prepaid Assets stood at $6.0 million in 2022, then slumped by 47.08% to $3.2 million in 2023, then tumbled by 42.1% to $1.8 million in 2024, then fell by 1.9% to $1.8 million in 2025, then slumped by 42.66% to $1.0 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $1.0 million, $1.2 million, and $1.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Milestone Pharmaceuticals | 146.32 Mn | -25.18 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.04 Mn |
| Mar 31, 2026 | 1.21 Mn |
| Dec 31, 2025 | 1.81 Mn |
| Sep 30, 2025 | 2.58 Mn |
| Jun 30, 2025 | 748,000.00 |
| Mar 31, 2025 | 2.36 Mn |
| Dec 31, 2024 | 1.84 Mn |
| Sep 30, 2024 | 2.52 Mn |
| Jun 30, 2024 | 1.71 Mn |
| Mar 31, 2024 | 2.36 Mn |
| Dec 31, 2023 | 3.18 Mn |
| Sep 30, 2023 | 6.96 Mn |
| Jun 30, 2023 | 5.40 Mn |
| Mar 31, 2023 | 5.45 Mn |
| Dec 31, 2022 | 6.01 Mn |
| Sep 30, 2022 | 5.06 Mn |
| Jun 30, 2022 | 3.47 Mn |
| Mar 31, 2022 | 4.07 Mn |
| Dec 31, 2021 | 4.30 Mn |
| Sep 30, 2021 | 5.97 Mn |